Evaluation of the Metformin Effect on Methylglyoxal in Patients With Type 2 Diabetes
Status:
Unknown status
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This study is designed to investigate the effects of metformin, a commonly prescribed first
line medication for diabetes and recommended for prediabetes, on the levels of the
potentially tissue damaging reactive product (MG) in the blood and its cleared counterpart in
the urine (IMZ). The study will involve patients with elevated HbA1c randomized to receive
either metformin or a similar inactive placebo pill and a group of sex and age matched
volunteers without diabetes. Study participants will be recruited from the University of
Arizona Medical Center, South Campus clinics (Endocrine clinic, family medicine clinic and
general medicine clinic). Eighty patients with HbA1c >6.0% will be randomized to receive
either metformin or a similar inactive placebo for 6 weeks. The response of these patients
will be compared to 40 patients normal HbA1c <5.6% who will not receive either study
medication. Investigators will compare the plasma MG and urine IMZ concentration/content
between the 3 groups before and after the 6-week intervention. It is hypothesized that plasma
MG level in the metformin treatment group will be less than in the group taking the placebo
pills, while there will be no significant difference in MG level between the metformin
treatment group and the volunteers without diabetes.